Zinbryta risks outweigh benefits, European report

Multiple sclerosis treatment Zinbryta was withdrawn in March and now a review by the European Medicines Agency has found its risks outweigh its benefits. The review confirms the drug’s association with the risk of developing severe and potentially fatal immune reactions in the brain, liver and other organs. It was carried out by to the … Continue reading Zinbryta risks outweigh benefits, European report

MS treatment Zinbryta (daclizumab) withdrawn worldwide amid safety concerns

Disease modifying therapy daclizumab (Zinbryta) has been withdrawn from sale worldwide. Its manufacturers took the decision after reports that a number of people taking the treatment developed serious inflammatory brain disorders. That’s how the news was announced on the MS Society’s website. In the UK, the treatment will no longer be available via the country’s … Continue reading MS treatment Zinbryta (daclizumab) withdrawn worldwide amid safety concerns

New multiple sclerosis treatment to repair myelin is at phase 2 trial stage of development

Anti-LINGO-1 (also known as BIIB033) is a new MS treatment being development by the pharmaceutical company Biogen. It is currently being tested in people with optic neuritis, relapsing remitting MS and secondary progressive MS in phase 2 clinical trials. LINGO is a protein found in nerve cells and myelin-making cells called oligodendrocytes. Blocking the activity … Continue reading New multiple sclerosis treatment to repair myelin is at phase 2 trial stage of development